Cable Hill Partners LLC Has $3.99 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Cable Hill Partners LLC cut its holdings in Eli Lilly and Company (NYSE:LLY) by 3.5% in the 2nd quarter, Holdings Channel.com reports. The firm owned 17,373 shares of the company’s stock after selling 630 shares during the quarter. Eli Lilly and makes up about 0.9% of Cable Hill Partners LLC’s holdings, making the stock its 14th largest holding. Cable Hill Partners LLC’s holdings in Eli Lilly and were worth $3,987,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the business. Epoch Investment Partners Inc. boosted its position in Eli Lilly and by 1.7% during the 2nd quarter. Epoch Investment Partners Inc. now owns 288,668 shares of the company’s stock worth $66,255,000 after acquiring an additional 4,720 shares during the last quarter. Intellectus Partners LLC acquired a new position in Eli Lilly and during the 2nd quarter worth approximately $807,000. Natixis Investment Managers International boosted its position in Eli Lilly and by 8.0% during the 2nd quarter. Natixis Investment Managers International now owns 100,701 shares of the company’s stock worth $23,163,000 after acquiring an additional 7,454 shares during the last quarter. Natixis boosted its position in Eli Lilly and by 306.4% during the 2nd quarter. Natixis now owns 93,468 shares of the company’s stock worth $21,453,000 after acquiring an additional 70,469 shares during the last quarter. Finally, Mirova boosted its position in Eli Lilly and by 3.1% during the 2nd quarter. Mirova now owns 33,580 shares of the company’s stock worth $7,707,000 after acquiring an additional 999 shares during the last quarter. 81.65% of the stock is owned by hedge funds and other institutional investors.

In related news, major shareholder Lilly Endowment Inc sold 236,542 shares of the firm’s stock in a transaction dated Tuesday, August 3rd. The stock was sold at an average price of $256.12, for a total value of $60,583,137.04. Following the sale, the insider now directly owns 108,537,712 shares of the company’s stock, valued at $27,798,678,797.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 492,615 shares of company stock worth $128,197,709 over the last ninety days. 0.13% of the stock is currently owned by insiders.

A number of equities research analysts have recently issued reports on the company. Berenberg Bank upgraded Eli Lilly and from a “hold” rating to a “buy” rating and upped their price objective for the stock from $240.00 to $270.00 in a research note on Monday. Citigroup upgraded Eli Lilly and from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $210.00 to $265.00 in a research note on Wednesday, September 29th. They noted that the move was a valuation call. Cantor Fitzgerald upped their price objective on Eli Lilly and from $245.00 to $300.00 and gave the stock an “overweight” rating in a research note on Thursday, June 24th. Argus upped their price objective on Eli Lilly and from $225.00 to $300.00 and gave the stock a “buy” rating in a research note on Monday, August 9th. Finally, Morgan Stanley upped their price objective on Eli Lilly and from $207.00 to $275.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $258.22.

Shares of LLY traded down $0.75 during trading hours on Thursday, hitting $235.69. 26,078 shares of the company were exchanged, compared to its average volume of 3,457,061. The company has a market cap of $226.03 billion, a price-to-earnings ratio of 35.45, a P/E/G ratio of 1.86 and a beta of 0.25. Eli Lilly and Company has a fifty-two week low of $129.21 and a fifty-two week high of $275.87. The company has a quick ratio of 0.89, a current ratio of 1.15 and a debt-to-equity ratio of 2.21. The firm’s fifty day moving average is $247.65 and its 200 day moving average is $223.58.

Eli Lilly and (NYSE:LLY) last released its earnings results on Monday, August 2nd. The company reported $1.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.89 by ($0.02). The company had revenue of $6.74 billion for the quarter, compared to analyst estimates of $6.59 billion. Eli Lilly and had a return on equity of 119.12% and a net margin of 22.71%. The business’s revenue for the quarter was up 22.6% compared to the same quarter last year. During the same period last year, the company posted $1.89 earnings per share. Analysts anticipate that Eli Lilly and Company will post 7.87 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly & Co engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm’s products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity.

Featured Article: What is the QQQ ETF?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.